Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 2/2022

01-04-2022 | Lymphoma | Images

NK-Lymphoblastic Leukemia/Lymphoma: An Enigma

Authors: Karthik Srevatsa, Garima Jain, Deepam Pushpam, Aparna Ningombam, Anita Chopra

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2022

Login to get access

Excerpt

A 59-year-old man was investigated for fever, headache, and blurring of vision. On physical examination, he had hepatosplenomegaly. PET/CT revealed multiple intra-thoracic and intra-abdominal lymphadenopathy. A complete blood count showed leucocytosis (90.4 × 109 /L) with anemia (9.8 g/dL) and thrombocytopenia (77 × 109/L). The peripheral blood smear showed the presence of 75% pleomorphic, medium- to large-sized atypical cells with mostly irregularly shaped nuclei, high nuclear/cytoplasmic ratio, and immature, blastic chromatin with multiple nucleoli (Fig. 1A). Bone marrow examination revealed infiltration by 80% of similar morphology cells. On immunophenotyping, these cells were: CD45bright+/CD2+/CD7+/CD43dim+/CD94+/cytoplasmicCD3/CD5/CD28/CD4/CD8/TdT/CD19/CD10/CD117/CD33/CD13/CD56/Perforin/TCRαβ/TCRγδ/HLA-DR+/cytoplasmicCD79a/CD30 /CD57 /CD16/CD11c/CD25/cytoplasmic MPO/CD64 /CD14. This suggested a diagnosis of Natural Killer (NK) cell lymphoblastic leukemia/lymphoma. The patient was started on cyclophosphamide, dexamethasone, and etoposide. However, he developed tumor lysis syndrome and succumbed to the disease.
Metadata
Title
NK-Lymphoblastic Leukemia/Lymphoma: An Enigma
Authors
Karthik Srevatsa
Garima Jain
Deepam Pushpam
Aparna Ningombam
Anita Chopra
Publication date
01-04-2022
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2022
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-021-01511-z

Other articles of this Issue 2/2022

Indian Journal of Hematology and Blood Transfusion 2/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine